Proteinuria, mostly of renal origin, a test result detected observed in patients taking rosuvastatin 40 mg and higher, and in most cases is transient. This proteinuria is not a symptom of acute or progressive renal disease. The total number of cases of serious renal complications seen with the use of rosuvastatin 40 mg. In applying the drug Tevastor at a dose of 40 mg is recommended to monitor renal function.Effects on skeletal muscles (myalgia, myopathy and rhabdomyolysis rarely) observed in patients taking the drug Tevastor, in particular in a dose of 20 mg. Very rare cases of rhabdomyolysis have been reported with the use of ezetimibe with masterone reductase. The likelihood of developing rhabdomyolysis, as the application of rosuvastatin and other reductase inhibitor, higher at a dose of 40 mg.
Activity Determination of should not be carried out after intense exercise or when there are other possible reasons for the increased activity due to the likely distortions received results. If the initial activity significantly increased (, 5-7 days should be a re-measurement. You should not begin therapy if a second test confirms the initial activity .
It should warn patients about the need to immediately inform your doctor if new, previously not marked symptoms of unexplained muscle pain, weakness or cramps, especially combined with fever and malaise. Therapy should be discontinued activity 5 times above or when there are severe symptoms of muscle, causing constant discomfort. With the disappearance of symptoms and normalization of the masterone activity, consideration should be given to re-use of rosuvastatin with minimum dose and close monitoring. Routine monitoring of creatine kinase activity in the absence of symptoms is not appropriate. It is recommended to diagnose liver function before and 3 months after initiation of therapy. In patients with secondary hypercholesterolaemia caused by hypothyroidism or nephrotic syndrome, should be the primary treatment of the disease before prescribing the drug Tevastor.
Effects on ability to management of motor transport and work with technology
research aimed at studying the effect of the drug on Tevastor capacity for road management and work with the technique, was conducted. In applying the drug masterone care should be taken due to the fact that the possible development of dizziness.